Diagnostic and Therapeutic Challenges of Mycobacterium avium Complex Pulmonary Disease in Patients with Lung Cancer: A Retrospective Case Series
Infection and Drug Resistance · 2026-11 · Volume 19 · 1-12
DOI: 10.2147/idr.s645451 ↗Kurz gefasst
Fachartikel in der Zeitschrift Infection and Drug Resistance, 2026-11. Verfasst von Ruiyue Gao und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Objective
To describe the clinical characteristics, diagnostic challenges, and therapeutic management of Mycobacterium avium complex pulmonary disease (MAC-PD) in patients with lung cancer, and to highlight the diagnostic limitations and treatment dilemmas encountered in this vulnerable population.
Methods
We retrospectively reviewed four patients with lung cancer complicated by MAC-PD at a tertiary respiratory center in Beijing, China, between 2017 and 2025. Clinical data, cancer characteristics, underlying structural lung disease, anticancer treatments, radiological findings, microbiological results, anti-MAC regimens, and clinical outcomes were analyzed. Diagnostic methods included sputum culture, bronchoscopy with bronchoalveolar lavage fluid (BALF) next-generation sequencing (NGS), and T-SPOT.TB. The 2020 ATS/ERS/ESCMID/IDSA diagnostic framework for NTM-PD was referenced for case evaluation.
Results
All four patients were male, aged 66– 73 years (mean 70.5 years), with underlying bronchiectasis or structural lung abnormalities. Two had lung adenocarcinoma and two had squamous cell carcinoma. MAC-PD was detected during early anticancer therapy (n=1), during combined chemotherapy and immunotherapy (n=1), or after lung cancer surgery (n=2). Chest CT showed centrilobular nodules, tree-in-bud opacities, bronchiectasis, cavitary lesions, destroyed lung, and bronchopleural fistula, overlapping with tumor progression or bacterial pneumonia. MAC was identified by BALF NGS in three patients and sputum culture in one. In Cases 1, 2, and 4, clinical diagnoses of suspected MAC-PD were supported by BALF NGS without confirmatory mycobacterial culture. Causative organisms included M. intracellulare (n=2) and Mycobacterium avium complex not further speciated (n=2). All patients received multidrug anti-MAC therapy. Regimens were modified in two patients due to adverse events or drug-drug interactions. Two patients with destroyed lung and bronchopleural fistula had poor outcomes despite prolonged therapy (30 months and 17 months, respectively). No patient underwent antimicrobial susceptibility testing.
Conclusion
MAC-PD should be considered in lung cancer patients with bronchiectasis or structural lung disease when new centrilobular nodules, tree-in-bud opacities, cavitary lesions, or progressive lung destruction cannot be explained by tumor progression. Early bronchoscopy with both culture and NGS is essential; NGS should be regarded as an adjunct to, not a substitute for, culture-based diagnosis and susceptibility testing. Drug-drug interactions—particularly rifamycin-antifungal combinations—require proactive evaluation, and the combination of rifapentine with voriconazole should be avoided. Once destroyed lung develops, treatment options are limited and prognosis is poor, underscoring the importance of early detection. Keywords: Mycobacterium avium complex pulmonary disease, MAC-PD, lung cancer, case series, drug-drug interactions, next-generation sequencing, bronchiectasis, destroyed lung, antimicrobial susceptibility testing
Zitieren
APA
Gao, R., & Zhu, M. (2026). Diagnostic and Therapeutic Challenges of Mycobacterium avium Complex Pulmonary Disease in Patients with Lung Cancer: A Retrospective Case Series. Infection and Drug Resistance, Volume 19, 1-12. https://doi.org/10.2147/idr.s645451
Vancouver
Gao R, Zhu M. Diagnostic and Therapeutic Challenges of Mycobacterium avium Complex Pulmonary Disease in Patients with Lung Cancer: A Retrospective Case Series. Infection and Drug Resistance. 2026;Volume 19:1-12. doi:10.2147/idr.s645451
BibTeX
@article{Gao2026,
author = {Gao, Ruiyue and Zhu, Min},
title = {Diagnostic and Therapeutic Challenges of Mycobacterium avium Complex Pulmonary Disease in Patients with Lung Cancer: A Retrospective Case Series},
journal = {Infection and Drug Resistance},
year = {2026},
volume = {Volume 19},
pages = {1--12},
doi = {10.2147/idr.s645451}
}
EUVIMED